Skip to main content

Table 2 Treatment Outcomes Among Osteosarcoma Patients Treated in Clinical Trial of Palliative Radiotherapy and Intra-tumoral Autologous NK Cells

From: Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial

Patient Age (years) Total NK Cells Injected (× 106) Toxicity Status Survival Time (months) Cause of Deatha 6-Month Metastasis-Free Survivalb
1 14.8 30.3   Dead 2.4 Metastases No
2 9.1 25.34 Infection at injection site Alive 8.1 n/a Yes
3 9.1 547   Alive 11.2 n/a Yesc
4 5.8 254.33   Alive 6.0 n/a Yes
5 1.2 102.63 Grade 3 fever/chills/dehydration attributed to rhIL-2 reaction; Infection at injection site requiring surgery Dead 8.1 Metastases Yes
6 6.3 216.4 Infection at injection site requiring surgery Dead 4.1 Perforated ulcer No
7 7.5 234   Dead 2.9 Pathologic fracture/ metastases No
8 5.0 305   Dead 1.6 Pathologic fracture No
9 8.9 355   Alive 7.6 n/a Yes
10 10.2 132   Dead 5.0 Metastases No
  1. aAnimals were euthanized at owner’s request following diagnosis of index event
  2. bFreedom from pulmonary metastasis 6 months after enrollment was the primary endpoint of the clinical trial
  3. cPatient demonstrated resolution of suspicious pulmonary nodule post-radioimmunotherapy